Bio Nano Consulting to Provide Product Development Services to a Top 5 Pharma Company
News Jan 27, 2009
Bio Nano Consulting (BNC), the specialist bio-nanotechnology product development consultancy, has signed a collaborative agreement with a Top 5 pharma company to develop new assay systems for their product discovery and development.
The agreement is the eighth major contract won by BNC in 2008, and follows the completion in mid December of a second contract with Targanta Therapeutics Corporation, in which BNC used cantilever-array assay system technology to analyze the mechanism of action of Targanta’s novel lipoglycopeptide antibiotic, oritavancin.
Commenting on the new contract, Dr David Sarphie, CEO of Bio Nano Consulting said, “Nanotechnology is finding more and more applications in industry, and BNC is developing a well-deserved reputation within the pharmaceutical, biotech, medtech and healthcare industries for providing novel approaches in research and development. With the unparalleled expertise of scientists at UCL’s London Centre for Nanotechnology, the Institute of Biomedical Engineering at Imperial College and the National Physical Laboratory, BNC is ideally placed to offer nanotechnology solutions in these sectors”.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE